Jason A. Mouabbi and Sara Tolaney
Aug 29, 2025, 16:46
Surprising Benefits of Adjuvant Abemaciclib in Breast Cancer Treatment
Jason A. Mouabbi, Assistant Professor at MD Anderson Cancer Center, shared a post by Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, on X, adding:
”I totally agree! Showing OS benefit in the adjuvant setting of early stage HR+ HER2-ve is not easy at all! In fact I did not expect it! That’s why this is really impressive!”
Quoting Sara Tolaney‘s post:
”Very big news out today– adjuvant abemaciclib improves overall survival in high-risk ER+ breast cancer at ~7 years of follow up! Showing OS benefit in this setting is not easy and nice to see what an incredible impact adj cdk4/6i can have for our patients!”
More posts about Jason A. Mouabbi on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 29, 2025, 16:46
Aug 29, 2025, 16:31
Aug 29, 2025, 15:56
Aug 29, 2025, 15:55
Aug 29, 2025, 15:30